
**Copyright:**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**DOI link to article:**

[https://doi.org/10.1136/flgastro-2015-100651](https://doi.org/10.1136/flgastro-2015-100651)

**Date deposited:**

06/09/2017

This work is licensed under a [Creative Commons Attribution-NonCommercial 3.0 Unported License](http://creativecommons.org/licenses/by-nc/3.0/).
RESEARCH

Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome

Anton Emmanuel,1 Darryl Landis,2 Mark Peucker,3 A Pali S Hungin4

ABSTRACT

Objective To determine rates of faecal biomarker results capable of suggesting potentially treatable causes of irritable bowel syndrome (IBS) symptomatology in a population of patients with symptoms of IBS who meet Rome III criteria for that condition.

Design Descriptive, retrospective study in which faecal biomarker results (dichotomised into ‘normal’ and ‘abnormal’ values) were related to data from patient-completed questionnaire data identifying demographics, Rome III criteria for IBS and IBS phenotype (IBS-D, IBS-C, IBS-M and IBS-U).

Setting Commercial reference laboratory.

Patients Individuals whose physicians ordered faecal biomarker testing for evaluation of chronic abdominal symptoms consistent with IBS.

Interventions None.

Main outcome measures Rates of occurrence of abnormal results on any of seven faecal biomarkers suggesting a treatable cause for IBS symptoms.

Results Abdominal symptoms meeting Rome III criteria for IBS were present in 3553 records (the population), which were subjected to further analysis. Abnormal biomarker results (the outcomes) occurred in 94% of cases; 73% and 65% of records indicated growth of a bacterial potential pathogen and low growth of beneficial organisms, respectively. Abnormal results for all other faecal biomarkers occurred with frequencies from 5% to 13%. Frequency of abnormal results for elastase, calprotectin, eosinophil protein X, and beneficial organisms rose significantly with age, and differed significantly across IBS phenotypes.

Conclusions A large proportion of patients manifesting symptoms meeting Rome III IBS diagnostic criteria have faecal biomarker results indicating potential underlying, treatable causes of their symptoms. Faecal biomarker testing is an appropriate means of identifying potentially treatable causes of IBS symptoms.

INTRODUCTION

Abdominal symptoms consistent with irritable bowel syndrome (IBS) are highly prevalent and impose substantial burdens on sufferers and the healthcare system in general. A positive diagnosis can be made using Rome Foundation criteria for IBS, but such clinical criteria do not offer guidance on management of any individual patient’s condition, leading to continued use of invasive and costly diagnostic imaging techniques that produce meaningful results in only a small fraction of cases.1,2

Current evidence indicates that symptoms associated with IBS, including those contributing to a positive diagnosis by Rome III and other clinical criteria, frequently arise from a number of independent, and often treatable, conditions.3 The actual frequency of the presence of such underlying causes of IBS symptoms, however, remains unknown.

In the present study, therefore, we attempted to characterise the frequency and distribution of results for seven faecal biomarkers capable of suggesting underlying conditions that could be responsible for producing symptoms in accordance with those diagnostic criteria, in a group of subjects with chronic abdominal pain meeting current Rome III IBS criteria.

METHODS

This study was a retrospective, observational evaluation of faecal biomarker results in a population of subjects with abdominal pain, verified by a validated, self-administered questionnaire to have IBS by Rome III criteria.

Setting The study was conducted by Genova Diagnostics (GDX, Asheville, North Carolina, USA).

Correspondence to Dr Anton Emmanuel, GI Physiology Unit, University College Hospital, 235 Euston Road, London NW1 2BU, UK; a.emmanuel@ucl.ac.uk

Received 8 December 2015 Revised 8 February 2016 Accepted 12 February 2016 Published Online First 4 March 2016


1GI Physiology Unit, University College Hospital, London, UK
2Medical Affairs, Genova Diagnostics, Inc., Asheville, North Carolina, USA
3Care-Safe, LLC, Waltham, Massachusetts, USA
4School of Medicine, Pharmacy and Health, Wolfson Research Institute, Queen’s Campus, Durham University, Stockton on Tees, UK
Concerns about potential sources of GI symptomatology. Faecal biomarker testing provided by GDX in response to their concerns led to the study described in this paper. Most patients presenting to primary care physicians who use faecal biomarker tests were at the discretion of the referring physician. There was no study-mandated intervention; the ordering of faecal biomarker tests was at the discretion of the referring physician.

### Patient population

GDX serves a predominantly US-based ambulatory patient population; faecal biomarker testing is typically ordered by primary care physicians when patients present with gastrointestinal (GI) symptoms without obvious cause. Thus, records included in this study represent a ‘real world’ population selected by primary care providers who use faecal biomarker testing provided by GDX in response to their concerns about potential sources of GI symptomatology.

For this study, only patients whose age was indicated as ≥18 years, who had faecal testing for any of the biomarkers of interest, and whose Rome III questionnaire provided a positive diagnosis of IBS were included. Not every Rome III-confirmed subject had every biomarker ordered on test requisitions. There was no study-mandated intervention; the ordering of faecal biomarker tests was at the discretion of the referring physician.

### Faecal biomarkers

Based on previous work, we selected seven target biomarkers each of which produced abnormal results in more than 2% of subjects with abdominal symptoms consistent with IBS (table 1). The clinical validity and diagnostic performance of these target biomarkers have been summarised in other published studies.

### Statistical analyses

Faecal biomarker results were dichotomised into ‘normal’ and ‘abnormal’ categories based on the cut-offs shown in table 1. Frequency distributions for abnormal results were prepared for each biomarker and for other study variables, including age, gender and Rome III IBS subcategory. Differences in distribution of abnormal biomarker results between age, gender, and IBS subcategories were analysed by Chi-square for significance.

---

**Table 1** Targeted faecal biomarkers in patients with Rome III-confirmed IBS

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Assay used</th>
<th>Definition of abnormal result</th>
<th>Interpretation of abnormal result in context of IBS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture for pathogenic or potentially pathogenic bacteria*</td>
<td>Routine culture.</td>
<td>Present.</td>
<td>Suggestive of GI pathogenic disease.</td>
</tr>
<tr>
<td>Culture for beneficial bacteria (Lactobacillus, Bifidobacterium)</td>
<td>Routine culture.</td>
<td>Growth in 1 or fewer quadrants (Lacto)/2 or fewer quadrants (Bifido).</td>
<td>Reduced numbers of beneficial symbionts (dysbiosis).</td>
</tr>
<tr>
<td>Pancreatic elastase-1</td>
<td>Monoclonal antibody EIA (Pancreatic elastase 1 stool test, ScheBo Biotech USA, Colorado Springs, Colorado, USA).</td>
<td>&lt;200 μg/g</td>
<td>Suggestive of exocrine pancreatic insufficiency.</td>
</tr>
<tr>
<td>Calprotectin</td>
<td>ELISA, PhiCal, Lysaker, Norway.</td>
<td>&gt;50 μg/g</td>
<td>Suggestive of neutrophilic inflammation, for example, IBD.</td>
</tr>
<tr>
<td>Eosinophil protein X</td>
<td>Modified EDN sandwich ELISA†, MBL International, Woburn, Massachusetts, USA.</td>
<td>&gt;7 μg/g</td>
<td>Suggestive of food allergy or parasites (or other causes of eosinophilic inflammation).</td>
</tr>
<tr>
<td>Parasites†</td>
<td>EIA for Entamoeba histolytica/dispar, Giardia lamblia, Cryptosporidium; light microscopy for all other parasites.</td>
<td>Present on microscopic exam, all other parasites: present on microscopic exam.</td>
<td></td>
</tr>
<tr>
<td>Occult blood</td>
<td>Hemoseure one-step iFOB test, (Hemosure Irwindale, California, USA).</td>
<td>Present.</td>
<td>Suggestive of inflammation, malignancy, enteric infection.</td>
</tr>
</tbody>
</table>

Seven biomarkers were chosen for determination of prevalence of abnormal results in a Rome III-confirmed IBS population. All of these have been reported as evidence of potential aetiological roles in production of IBS symptoms.

*See online supplementary table 1 for bacterial/fungal pathogen designations.
†Laboratory-derived test (LDT) based on.
‡See online supplementary table 2 for parasite pathogen designations.
§Detection by ELISA (EIA).
EDN, eosinophil-derived neurotoxin; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; iFOB, immunochemical faecal occult blood; MBL, Medical and Biological Laboratories Co, Ltd.
RESULTS
A total of 24,258 faecal specimens were received during the study period. Of those, 7,503 included completed demographic surveys; calculation of a true survey response rate was not possible because it could not be confirmed that all specimen collection kits in use during the study period included survey forms. The flow diagram in figure 1 illustrates further selection of records based on age and record completion data.

After exclusion of records missing age and Rome III data, and selection of those indicating IBS by Rome III criteria, 3,553 records were included for further analysis.

Gender, age and Rome III subcategory distributions
The study population of 3,553 subjects consisted of 2,860 (80.5%) women and 693 (19.5%) men. There were 1,892 (53.3%) 18–49-year-old subjects, with 1,348 (37.9%) aged 50–69 years, and 313 (8.8%) aged 70 years or greater.

Figure 2 shows the distribution of Rome III subcategories of IBS in the total population of Rome III-confirmed subjects.

General distribution of abnormal biomarker results
Figure 3 shows the frequency of abnormal biomarker results in the entire Rome III-confirmed study population; not all subjects were tested for all biomarkers, therefore, the total number of subjects tested for each biomarker appears in parentheses.

Tests for the biomarkers pancreatic elastase-1 (PE-1), faecal calprotectin (FC) and eosinophil protein X (EPX) produce continuous results, with ‘abnormal’ being defined as values above or below clinically relevant cut-offs as shown in table 2.

We examined possible relationships between several individual biomarkers. For example, elevated levels of EPX and FC or the presence of faecal occult blood (FOB) may each indicate mucosal inflammation and parasitosis may cause inflammation. In our cohort only 48.9% (112/229) of subjects with elevated EPX levels also had an elevated FC value. In IBS subjects with a documented parasite, 7.3% (14/193), 4.3% (9/210) and 3.1% (3/97) had an abnormal FC, EPX or FOB, respectively.

Distribution of abnormal biomarker results by gender
There was a significant gender effect on several of the biomarkers studied. There were significantly more male than female subjects with abnormal PE-1 results (17.2% vs 12.4%, p<0.001). A small but significant female predominance was seen in abnormally low levels of growth of Bifidobacteria/Lactobacillus, with abnormal results in 67.3% of women versus 57.1% in men (p<0.001). All other abnormalities were evenly gender distributed.

Distribution of abnormal biomarker results by age
The frequency of abnormal results for several individual biomarkers rose significantly with increasing age categories, as shown in table 3. Subjects in the middle age group (50–69 years) had significantly greater frequency of abnormal commensal organisms (low growth of Bifidobacteria/Lactobacillus), compared with the youngest and oldest groups.

No significant age effects were seen on the rates of abnormal results for occult blood, parasites or bacterial potential pathogens.

Distribution of abnormal biomarkers by Rome III IBS subcategory
Table 4 shows significant differences in the occurrence of abnormal faecal biomarker results by Rome III IBS subcategory (the category IBS-U included only 32 records (0.9%), and was dropped from subsequent analyses).

No significant effects of IBS subcategory were seen in rates of abnormal results for FOB, parasites or PE-1. There were no significant differences by Rome III subcategory for having abnormal results for the outcome ‘any abnormal’ (IBS-C, 24.4%, IBS-D, 28.8%, IBS-M 25.0%).

DISCUSSION
The present study represents, to our knowledge, the largest population of patients with Rome III-confirmed IBS in which a complete characterisation of demographics and IBS subtypes has been attempted, and the only one to date in which an array of faecal biomarker results has been described. As noted, there was no control group; this study was not intended to evaluate the discriminatory power of any of the biomarkers as diagnostic of IBS; in fact, subjects in whom abnormal biomarkers were detected would be candidates for an alternate diagnosis based on those results, and a broader workup, potentially including endoscopy in certain cases, would be appropriate.

The principal findings in this study are that the rate of abnormal results on the faecal biomarkers evaluated is quite high, at 94% overall; we identified significant differences in faecal biomarker patterns occurring by age category, and by IBS phenotype. This study confirms and strengthens our previous findings in a study of patients with presumed IBS based on ICD-9 codes alone, demonstrating quite similar distributions of abnormal biomarker results in a population confirmed to have IBS by Rome III criteria. The current study also includes analyses of biomarker results by Rome III subcategories, and presents a more detailed distribution of results of biomarker tests returning continuous results.

Implications of abnormal biomarkers in an IBS population

Changes in our understanding of IBS have led to the recognition that the syndrome is unlikely to have a single, identifiable cause, but also that it ought no longer to be considered a diagnosis of exclusion. Rather, the notion that IBS is an ‘umbrella’ diagnosis of a phenotype defined by symptoms that are common to a number of discrete disease processes has gained currency.3 15

In the present study, we have taken initial steps to characterise a group of biomarkers capable of suggesting alternative, treatable conditions or underlying causes producing the IBS phenotype as defined by Rome III criteria. The intention is to improve outcomes of patients classified as meeting IBS criteria by identifying and treating reversible disorders. Ultimately, it is to be hoped that faecal biomarker testing will have the effect of shrinking the number of patients in whom the diagnosis of IBS, without further specification, is the end point of the diagnostic evaluation.

Our analysis suggests that parallel assessment of multiple biomarkers may have significant clinical utility in differentiating specific underlying aetiologies of IBS presentations. For example, FC and EPX (assessing neutrophilic inflammation and eosinophilic inflammation, respectively) appear to be independent biomarkers. This finding is consistent with other published studies demonstrating that EPX may be a marker of treatment response in collagenous colitis, which is thought to have more eosinophilic involvement than inflammatory bowel disease (IBD).16 17

Consistent with our previous work in a non-Rome III-confirmed IBS population,4 we identified a high overall rate of abnormal findings on selected faecal biomarkers. The two microbiota-related biomarkers, bacterial potential pathogens and abnormal growth of...
the beneficial commensals *Bifidobacteria* and *Lactobacillus*, accounted for a large proportion of abnormal results. These are non-standard biomarkers, and accurate values for their rates in healthy populations are not known, so it is possible that these findings have relatively little significance.

On the other hand, there is increasing evidence from other studies that community-level dysbiosis is a highly prevalent, important and potentially contributory factor to IBS, particularly in the diarrhoea-predominant subtype.\(^{15,18}\)

Others have shown, using 16S rRNA gene sequencing by PCR, that significant phylotype-level alterations exist in the intestinal microbiota of patients with IBS in comparison with control subjects, that such differences persist between certain IBS subtypes, and that patients with IBS carry microbiota of significantly less biodiversity than do healthy control subjects.\(^{19-24}\)

These studies appear to suggest that our culture-based result may indeed be a rough indicator of shifted microbial patterns in IBS, and make a case for further study using our faecal biomarkers in combination with advanced microbiome genomic sequencing.

### Table 2 Distribution of results for continuous biomarkers

<table>
<thead>
<tr>
<th>PE-1</th>
<th>Count (N=2628)</th>
<th>Per cent</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\geq 200)</td>
<td>2278</td>
<td>86.68</td>
</tr>
<tr>
<td>101–199</td>
<td>234</td>
<td>8.90</td>
</tr>
<tr>
<td>(\leq 100)</td>
<td>116</td>
<td>4.41</td>
</tr>
<tr>
<td>Total abnormal results</td>
<td>350</td>
<td>13.3</td>
</tr>
<tr>
<td>FC</td>
<td>Count (N=2667)</td>
<td>Per cent</td>
</tr>
<tr>
<td>(\leq 50)</td>
<td>2367</td>
<td>88.75</td>
</tr>
<tr>
<td>51–120</td>
<td>161</td>
<td>6.04</td>
</tr>
<tr>
<td>(&gt;120)</td>
<td>139</td>
<td>5.21</td>
</tr>
<tr>
<td>Total abnormal results</td>
<td>300</td>
<td>11.25</td>
</tr>
<tr>
<td>EPX</td>
<td>Count (N=2656)</td>
<td>Per cent</td>
</tr>
<tr>
<td>(\leq 2)</td>
<td>1904</td>
<td>71.69</td>
</tr>
<tr>
<td>(&gt;2\leq 7)</td>
<td>520</td>
<td>19.58</td>
</tr>
<tr>
<td>(&gt;7)</td>
<td>232</td>
<td>8.73</td>
</tr>
<tr>
<td>Total abnormal results</td>
<td>232</td>
<td>8.73</td>
</tr>
</tbody>
</table>

EPX, eosinophil protein X; FC, faecal calprotectin; PE-1, pancreatic elastase-1.

### Implications of abnormal biomarkers by IBS subtype

We found substantial differences between IBS subgroups in terms of biomarker results. Patients in the IBS-D subcategory had significantly higher rates of abnormal calprotectin, EPX and bacterial potential pathogens, compared with the IBS-C and IBS-M...
groups. Compared with IBS-M, patients in the IBS-D and IBS-C groups had significantly higher and lower rates of abnormal calprotectin and EPX, respectively. These findings appear to suggest biological differences between these subgroups, and to represent greater inflammatory responses in patients with IBS-D than in patients with IBS-C.

Subjects in the IBS-D group also had a higher rate of bacterial potential pathogens (see online supplementary table 1) compared with patients with IBS-M, though the numerical difference was small. Given that these were culture-based results, and that the definition of ‘potential pathogen’ is to some extent arbitrary, further study of the composition of the entire GI microbiome might shed clearer light on the role of various bacterial taxa in the etiopathogenesis of IBS.

Our findings in these regards appear consistent with previous work by others suggesting that patients with IBS-D have higher rates of both low-grade inflammation and dysbiosis.

Future studies should focus on the clinical utility of faecal biomarkers in management of patients whose symptoms meet Rome III criteria for IBS. It has already been shown using retrospective medical claims analysis that a structured faecal biomarker panel can reduce healthcare costs and unnecessary utilisation of services in evaluating patients with abdominal symptoms consistent with having IBS. It is to be anticipated that such a structured panel, composed of carefully selected biomarkers, will be shown prospectively to improve patient outcomes by directing management strategies towards the underlying, treatable causes of IBS symptoms, and at the same time to reduce utilisation of invasive and costly diagnostic procedures.

**Additional potential biomarkers in assessment of patients with IBS**

As IBS is increasingly recognised as a syndrome with multiple, possibly interacting, underlying causes, we anticipate the emergence of additional biomarkers that may be of substantial clinical utility in management.

For example, bile acid malabsorption (BAM) has been shown to be present in 25% or more of patients meeting clinical criteria for IBS, especially those with the IBS-D phenotype. The established standard for making the diagnosis of BAM is the 23-seleno-25-homotaurocholic acid test (SeHCAT), which is time-consuming and, while approved in most European countries, is as yet unavailable in the USA. Other studies, such as the 14C glycocholate test, involve radiation exposure, and may have difficulty in differentiation BAM from small intestinal bacterial overgrowth (SIBO), while measurement of serum 7 α-hydroxy-4-cholesten-3-one (C4) lacks sufficient clinical validation.

Direct measurement of bile acids in faecal matter may provide a simpler means of detecting BAM in patients with IBS, and elevated levels of faecal bile acids have indeed been identified in both patients with IBS-D and functional diarrhoea. Total faecal bile acid levels appear to have clinical validity, showing significant association with SeHCAT retention at day 3, and a good correlation (r=0.606) with serum C4 levels. A further potential advantage of direct faecal bile acid measurement is that low, rather than high levels of bile acids have been associated with IBS-C and functional constipation. Increased intestinal permeability (IP) has also recently been associated with syndrome-defining symptoms of IBS, and has been detected in mucosa of patients with IBS. Zonulin is a peptide signalling molecule that disrupts tight junctional proteins.

### Table 4 Proportion (%) of subjects with abnormal results by IBS subcategory

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>IBS-D</th>
<th>IBS-C</th>
<th>IBS-M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calprotectin*</td>
<td>13.4%</td>
<td>7.1%</td>
<td>10.9%</td>
</tr>
<tr>
<td>Eosinophil protein X**</td>
<td>12.2%</td>
<td>4.4%</td>
<td>8.0%</td>
</tr>
<tr>
<td>Low growth of <em>Bifido/Lacto</em>**</td>
<td>64.1%</td>
<td>71.6%</td>
<td>64.6%</td>
</tr>
<tr>
<td>Bacterial potential pathogens****</td>
<td>75.9%</td>
<td>71.0%</td>
<td>71.6%</td>
</tr>
</tbody>
</table>

Across-group significance: *p=0.0025; **p<0.001; ***p=0.0402; ****p=0.0285. Between-group significance, versus IBS-M: t<0.004; t<0.003; t<0.0114; t<0.0103.

IBS, irritable bowel syndrome.
between intestinal mucosal cells, leading to increased intestinal permeability (IP). Serological testing for zonulin has been demonstrated to correlate well with gold-standard lactulose/mannitol testing in patients with increased IP from several causes ($R^2=0.7935$). A recent study, published to date in abstract form only, has demonstrated elevated blood zonulin levels in subjects with IBS-D.

Intestinal dysbiosis, as noted above, is a common finding in patients with IBS. Improving accessibility of real-time, multiplex PCR sequencing may yet prove a useful biomarker of dysbiosis, which has been shown to respond well symptomatically to therapy with certain specific probiotic preparations such as *B. infantis* 35624.

Finally, symptoms of IBS induced by SIBO appear to respond well to treatment with the non-absorbed antibiotic rifaximin, increasing the need for a reliable and convenient biomarker of this condition. Several such biomarkers have recently been identified by Pimentel *et al.*, who suggest that antibodies against cytotoxic distending toxin B and vinculin have potential utility in distinguishing IBS-D from IBD; the immunological targets of these antibodies are known to be produced by bacteria that cause acute gastroenteritis and have been identified in animal models of postinfectious IBS.

As the role of various treatable conditions in patients meeting symptom criteria for IBS grows, it seems likely that these and other biomarkers will be of increasing interest in evaluating such patients and formulating targeted treatment plans.

**Limitations**

This was a retrospective study, comprised of data from subjects whose physicians ordered faecal biomarker testing as part of their clinical evaluation for abdominal symptoms. Thus, it is susceptible to selection biases, and is not presented as a true cross-sectional study representative of the general population of patients with IBS. This study does, however, represent the largest population of patients with Rome III-confirmed IBS described in detail, including data on faecal biomarker patterns. We therefore believe that, despite these limitations, it significantly extends our knowledge of the nature and characteristics of IBS.

Additionally, with a large number of patients being studied with a range of biomarkers, there is a danger of type I error. However, the biological plausibility of the types of biomarker profiles seen with specific ‘IBS’ phenotypes suggests that this is less likely.

**Conclusions**

This study showed a high rate of abnormal results on faecal biomarker testing, further confirming previous findings and supporting the concept of IBS as an ‘umbrella’ diagnosis with a suite of symptoms produced in common by a number of different and potentially treatable underlying causes. Future prospective studies may further delineate subpopulations with potentially treatable causes of symptoms consistent with IBS, ultimately shrinking the pool of patients in whom ‘IBS’ represents a diagnostic stopping point, instead refining diagnostic procedures and guiding therapy.

**Acknowledgements**

Teresa McBride assisted in the conduct of the analysis. Lupine Creative Consulting assisted with the preparation of the manuscript. Audrey Kopp provided administrative assistance in preparation and submission of the manuscript.

**Contributors**

All listed authors contributed to the conceptualisation, design, execution, analysis and writing of this manuscript.

**Competing interests** None declared.

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**


Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome

Anton Emmanuel, Darryl Landis, Mark Peucker and A Pali S Hungin

*Frontline Gastroenterol* 2016 7: 275-282 originally published online March 7, 2016
doi: 10.1136/flgastro-2015-100651

Updated information and services can be found at: [http://fg.bmj.com/content/7/4/275](http://fg.bmj.com/content/7/4/275)

These include:

**References**
This article cites 44 articles, 5 of which you can access for free at: [http://fg.bmj.com/content/7/4/275#BIBL](http://fg.bmj.com/content/7/4/275#BIBL)

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (52)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)